Fine Particle pMDI Formoterol/Beclomethasone in Asthmatics With and Without Spacer: Comparative Efficacy Evaluation

NCT ID: NCT01453881

Last Updated: 2015-03-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 45 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-04-30
• Study Completion Date: 2013-06-30

Brief Summary

Adequate pharmacological treatment controls symptoms in most asthmatics. Pressurized metered dose inhalers (pMDI)are the most used drug delivery devices. Valved holding chambers of different types and sizes have also been developed for use in combination with pMDI. The therapeutic efficacy of treatment depends on the amount of inhaled particles. The chambers can optimize lung deposition as it obviates lung-hand coordination and retain larger particles. The aim of this study is to compare the efficacy of the fine particle combination pMDI Beclomethasone/Formoterol in asthma control,with or without the aid of a spacer in patients without adequate asthma control on medium to high-dose inhaled steroids associated with long acting beta adrenergic drugs. The hypothesis is that there is no clinical efficacy difference between the two forms of drug administration.

Detailed Description

This is a randomized, parallel controlled study with blind outcome evaluation to compare the efficacy of the fine particle combination Beclomethasone/Formoterol administered with or without valved holding chamber (Vortex, Pari Innovative Manufacturers, VA - USA.

Eligible asthma patients will begin a 2-weeks run-in period to optimize their control medication use and to learn the correct relief pMDI use without holding chamber. After the run-in, patients with non-controled asthma symptoms (ACT score 19 or under)in spite the use of medium to high dose inhaled steroids and LABA association and able to use correctly the pMDI will be randomized (block-randomization) to receive the test medication combination to be used with or without the spacer device (VORTEX). Patients will be evaluated after 30 and 60 days. At days 15 (+,- 2) and 45 (+,- 2) they will have an incentive phone call.

ACT score (translated and validated to portuguese - Brazil), FEV1 (Kit-Micro spirometer, Cosmed, Italy), pMDI use and clinical evaluation will be obtained at initial visit (visit 0), randomization visit (visit 1)and at 30 and 60 days (visits 2 and 3). Extra-medication allowed at run-in period will be inhaled beta-2 bronchodilators for relief an at treatment period inhaled beta-2 agonists for relief and systemic steroids for exacerbations, with antibiotics as needed.

Endpoint evaluations will be proceeded by a treatment blinded investigator.In order to keep the concealment, the evaluations will be held in a different room and the patients instructed not to comment on treatment.

Subjects will be excluded at the treatment period in case of severe asthma exacerbation (hospital or ICU recovery or systemic steroid used for more than 5 days). They will be excluded also in case of concomitant ailments at discretion of the attending physician. These patients will be excluded from the per-protocol evaluation but will be described.

Sample size was calculated taking into account a relevant ACT score difference of 3 points and a SD of 4.4 (SCHATZ M et all. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol 2006;117:549-56). In order to be able to detect this difference with α and β errors of 5% and 20% respectively, the investigators calculated 32 patients per group.

Statistical analysis will be carried according to data distribution by a professional statistician.

Conditions

Asthma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Spacer

Beclomethasone/Formoterol 100/6mcg/puff pMDI 2 puffs two times/day with the aid of a Valved Holding Chamber - VORTEX

Group Type: EXPERIMENTAL

Spacer

Intervention Type: DEVICE

Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day with the aid of a Valved Holding Chamber - VORTEX

Comparator

Beclomethasone/Formoterol pMDI 100/6mcg/puff pMDI 2 puffs two times/day without the aid of a Valved Holding Chamber - VORTEX

Group Type: ACTIVE_COMPARATOR

Comparator

Intervention Type: DEVICE

Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day without the aid of a Valved Holding Chamber - VORTEX

Interventions

Spacer

Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day with the aid of a Valved Holding Chamber - VORTEX

Intervention Type: DEVICE

Comparator

Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day without the aid of a Valved Holding Chamber - VORTEX

Intervention Type: DEVICE

Other Intervention Names

BECLOMETHASONE EXTRA-FINE; FORMOTEROL; FOSTAIR; INNOVAIR; VORTEX

Eligibility Criteria

Inclusion Criteria

1. Adult, age 18 to 65 years, both sexes;

2. Clinical diagnosis of moderate to severe persistent asthma;

3. Nonsmoker;

4. Agree to participate and sign the Informed Consent;

5. ACT Score <= 19

6. FEV1 <= 80% of predicted;

7. History of response to FEV1 greater than 10%;

8. Patients who are already using Inhaled steroids at medium to high doses (Beclomethasone, budesonide, fluticasone) with longa-acting beta2 agonists (formoterol or salmeterol)

9. Proper use of metered-dose inhaler (after orientation)

Exclusion Criteria

1. Patient diagnosed with Chronic Obstructive Pulmonary Disease (COPD);

2. Current smokers or have stopped for less than 10 years;

3. Patients with a history of recent near-fatal asthma (less than 12 months);

4. Patients with a history of recent asthma hospitalization (last 6 months);

5. Patients with airway infection symptoms for less than 4 weeks;

6. Participation in any experimental study up to 1 (one) year from selection visit;

7. Hospitalization for any reason up to 8 weeks before selection visit;

8. History of liver, cardiac, renal, pulmonary or gastrointestinal diseases, epileptic, psychiatric or hematologic disorders, uncontrolled hypertension, rheumatology/orthopedic disorders that interferes with pMDI use;

9. Patients unable to properly use the pMDI during the selection

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Universidade Federal do vale do São Francisco

OTHER

Sponsor Role: collaborator

Universidade Federal de Pernambuco

OTHER

Sponsor Role: lead

Responsible Party

Jose Angelo Rizzo

PhD, MD, Medicine Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jose A Rizzo, PhD, MD

Role: PRINCIPAL_INVESTIGATOR

Universidade Federal de Pernambuco

Locations

Hospital das Clínicas - Universidade Federal de Pernambuco

Recife, Pernambuco, Brazil

Countries

Brazil

Other Identifiers

PTC 034/11

Identifier Type: -

Identifier Source: org_study_id